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Abstract
Background: Pain is the most troubling issue to patients with osteoarthritis (OA), yet current pharmacological
treatments offer only small-to-moderate pain reduction. Current guidelines therefore emphasise the need to
identify predictors of treatment response. In line with these recommendations, an individual patient data (IPD)
meta-analysis will be conducted. The study aims to investigate the relative treatment effects of topical
non-steroidal anti-inflammatory drugs (NSAIDs) and topical capsaicin in OA and to identify patient-level
predictors of treatment response.
Methods: IPD will be collected from randomised controlled trials (RCTs) of topical NSAIDs and capsaicin in
OA. Multilevel regression modelling will be conducted to determine predictors for the specific and the overall
treatment effect.
Discussion: Through the identification of treatment responders, this IPD meta-analysis may improve the
current understanding of the pain mechanisms in OA and guide clinical decision-making. Identifying and
prescribing the treatment most likely to be beneficial for an individual with OA will improve the efficiency
of patient management.
Systematic review registration: CRD42016035254
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Background
Osteoarthritis (OA) is the most common joint disorder
[1] and frequently affects the knee, hand, foot and hip
joints [2]. Risk factors for the development of OA in-
clude ageing, female gender, obesity, genetic factors, oc-
cupation, increased bone density and local factors such
as previous joint injury and joint shape or malalignment
[1–3]. OA is estimated to affect approximately 8.75
million people [2] and is the 11th largest contributor to
years lived with disability in the UK [4]. Pain is often the
most troubling issue to individuals with OA [5, 6] and is
the most common reason to present to the general prac-
titioner (GP) [1].
The nature of the pain in OA is variable, and this may
serve to further our understanding of the underlying
pain mechanisms. Hawker et al. found that OA pain,
particularly in the early stages, is strongly mechanical in
nature and is brought on in a predictable fashion by cer-
tain activities [6]. In more advanced disease, the pain is
often described as a continuous, dull ache interspersed
with shorter episodes of unpredictable, sharp pain [6]. A
subset of patients with OA also describes burning,
shooting or tingling pain that may be neuropathic in na-
ture [6–8]. Features of central sensitization, such as allo-
dynia [8], increased temporal summation, and impaired
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conditioned pain modulation [9], have also been identi-
fied in patients with OA. Furthermore, person-specific
characteristics such as catastrophizing, anxiety or de-
pression can also modify pain experience [10].
Within the recommendations endorsed by the Na-
tional Institute for Health and Care Excellence (NICE),
the European League Against Rheumatism (EULAR),
Osteoarthritis Research Society International (OARSI),
and the American College of Rheumatology (ACR), over
10 different pharmacological management options are
recommended for OA pain [1, 11–14]. However, the dif-
ference between treatment and placebo for commonly
recommended pharmaceutical treatments was found to
be 0.39 (95 % CI 0.31–0.47) [15], which is only equiva-
lent to about 10 % pain reduction [16].
It is possible that the modest effect size of OA treat-
ments arises from a mismatch between a patient’s pre-
dominant pain mechanism and the treatment most
effective for that mechanism. For this reason, treatment
guidelines have emphasised the need to identify predic-
tors of treatment response in order to tailor treatment
to the individual patient [11, 12, 17]. Identifying treat-
ment responders according to the presence of certain
clinical or investigational features would have two benefits.
Firstly, it would allow clinicians to select the treatment that
is most likely to benefit an individual patient. This is in
keeping with the principle in precision medicine whereby
understanding patient variability is considered to increase
the efficiency of patient management [18]. Secondly, it may
expand our understanding of the mechanisms that underlie
the pain experience in OA.
Two drugs recommended by the majority of guidelines
for hand and knee OA are topical non-steroidal anti-
inflammatory drugs (NSAIDs) and topical capsaicin [1,
11–14]. With regard to pain reduction, meta-analyses of
topical NSAIDs have shown a small-to-moderate effect
size compared to placebo [19–22]. NSAIDs are thought
to act by inhibiting the cyclooxygenase enzymes respon-
sible for the production of potent hyperalgesic mediators
[23, 24]. Topical capsaicin also appears to be superior to
placebo for pain relief in OA [25–27] and is believed to
act by causing defunctionalisation of nociceptive fibres
[28, 29]. As these topical treatments act by different
mechanisms, the comparison between the two treat-
ments may advance our understanding of the underlying
pain processes in OA. In addition, understanding the
characteristics that make a patient more likely to
respond to either of these treatments may also serve to
guide our choice of treatment for OA patients in the fu-
ture. Although several meta-analyses have shown that
topical NSAIDs and capsaicin are efficacious in OA,
little is known about who responds better to the treat-
ments and what the predictors of response to these
treatments are in OA.
The primary aim for this study is to investigate the
relative treatment effects of topical NSAIDs and topical
capsaicin in OA and to identify patient-level predictors
of treatment response.
Methods/design
We will conduct an individual patient data (IPD) meta-
analysis of randomised controlled trials (RCTs) to inves-
tigate the efficacy and predictors of topical NSAIDs or
topical capsaicin in individuals with OA. This is an alter-
native method that increases the power of subgroup
analysis compared to a single RCT. In addition, we will
conduct a network meta-analysis to examine the relative
effect between topical NSAIDs and topical capsaicin.
Study selection
Type of studies
Published and unpublished RCTs that evaluate the
efficacy of either topical NSAIDs or topical capsaicin
in participants with OA will be included. There will
be no language or geographical restrictions applied to
the studies.
Participants
Men and women with physician diagnosed OA, as de-
fined by the criteria endorsed by the ACR [30, 31]. Par-
ticipants with chronic joint pain, not due to rheumatoid
arthritis or other forms of arthritis, will also be included.
Studies investigating only OA patients and studies with
a subgroup of OA patients will be included, as long as
IPD data can be collected separately for the OA partici-
pants. Participants with back pain and other arthritic
pain, such as rheumatoid arthritis pain, will be excluded.
Types of interventions
Only topical NSAIDs or topical capsaicin will be studied.
These can include any formulation, dosage or drug
within the group. Salicylates, although pharmacologically
related to NSAIDs, will be excluded as their principal
action when applied topically is different from that of
topical NSAIDs [32]. Interventions involving ultrasound
or magnetophoresis of the topical treatment will also be
excluded. Controls will include placebo, active compara-
tors, continuing usual treatment, no treatment and
head-to-head comparison between topical NSAIDs and
topical capsaicin. Both open label and blinded studies
will be included.
Types of baseline assessments
As a minimum, studies will need to have assessed the
level of pain and important patient characteristics, in-
cluding age and gender, at baseline.
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Types of outcomes
For inclusion, trials must have an adequate assessment
of pain. As recommended by the OMERACT-OARSI
Initiative [33], measures of functional impairment and
patient’s global assessment will also be included in ana-
lysis when available.
Duration of follow-up will be a minimum of 1 week,
and the primary outcome will be measured at 4 weeks
or closest to 4 weeks.
Identification of eligible studies
A systematic database search of Medline (OVID interface,
1946 onwards), Embase (OVID interface, 1974 onwards),
AMED (OVID interface, 1985 onwards), CINAHL (EBS-
COhost interface, all years), Web of Science (Core Collec-
tion, 1900 onwards) and the Cochrane library (Wiley
interface, current issue) will be conducted to identify all
relevant RCTs of topical NSAIDs or topical capsaicin in
OA up until 16 November 2015. The search strategies are
based on those from the Cochrane reviews of topical
NSAIDs [24] and topical capsaicin [29, 34], with the
inclusion of other terms found through searching
the internet. The search strategies used can be found
in Additional file 1. Further studies will also be iden-
tified by contacting pharmaceutical suppliers of top-
ical NSAIDs and topical capsaicin, identified via the
British National Formulary, the electronic Medicines
Compendium and Clinicaltrials.gov, to ask for any
unpublished trial data. Reference lists of included
trials and reviews in the area will also be hand-
searched for any trials not found from searching the
databases. Review authors and collaborating authors
will be asked if they are aware of any eligible studies
not yet included.
References will be exported to Endnote, where dupli-
cates will be removed and eligibility for inclusion can be
assessed. One of the investigators (MP) will assess if
studies meet the inclusion criteria by screening the titles,
the abstracts and finally the full texts of articles found
through the systematic search. The list of included and
excluded studies will then be independently reviewed by
another investigator (YF), who will assess all full texts.
Any disagreements regarding the inclusion of studies
will be discussed between the two review authors. If no
consensus can be reached, a third investigator will be
consulted.
Data collection
The primary or corresponding author for all eligible tri-
als will be contacted and asked to collaborate on the
project. If they cannot be contacted, all co-authors listed
will be emailed. If none of the authors can be reached,
the institution where the research was carried out will
be contacted. Authors or institutions interested in
collaborating will be asked for access to the IPD from
the original study. The data will be accepted in any for-
mat and will be transferred into Microsoft Access for
storage. The data will be contributed to the OA Trial
Bank by the authors, as described by van Middelkoop
et al. [35].
Data extraction
Data extracted from the published reports will include
the distribution of participant demographics and disease
characteristics, study information and design, details of
the intervention and outcome measures. These will be
entered into a data extraction form by MP and will be
independently verified by another investigator.
Data contributed by the original study authors will
include patient characteristics such as age, gender and
body mass index (BMI). If available, other characteris-
tics will be collected including duration of complaints,
radiographic change, level of inflammation (e.g.
clinical or ultrasound effusion, CRP), type of pain (e.g.
neuropathic-like pain through PainDetect), central
sensitization (e.g. pain elsewhere through a question-
naire or pain threshold through quantitative sensory
testing) and psychological assessments (e.g. depres-
sion, anxiety, sleep disturbance, catastrophizing).
Study-level characteristics, such as setting (community
or hospital), allocation concealment, blinding, sample
size, risk of bias (low vs. high), intervention(s) used,
control(s) used, doses and formulations and duration
of follow-up will also be required. Finally, authors will
be asked to contribute the outcome measures of pain,
function and patient’s global assessment at baseline
and at all subsequent assessments.
All participants that have been randomised will be in-
cluded in the pooled database and will be included in
intention-to-treat (ITT) analyses. Secondary per-
protocol analyses will also be carried out.
Quality assessment
The quality of included studies will be assessed using a
modified version of the risk of bias tool recommended
by the Cochrane Collaboration [36] (Table 1 and
Additional file 2). It is composed of nine questions that
assess each of the domains set out in the risk of bias
tool. In contrast with the narrative nature of the
Cochrane tool, the modified version uses questions that
are scored as yes, no or unclear. Each question evaluates
the risk of bias in an objective manner, so as to minimise
the inter-rater disagreement that is associated with the
more subjective domains in the risk of bias tool [37]. As
the reviewer carrying out the quality assessment will
vary by the language of the study, these modifications
were aimed at reducing inter-rater variability in the
quality scoring.
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The first five questions of the modified tool assess
selection bias, performance bias and detection bias.
Each of these questions will be scored using the cri-
teria outlined by Cochrane [36]. The sixth question is
a measure of attrition bias, and similarly to the PE-
Dro and van Tulder quality scales [38], a cut-off for
acceptable drop-out rates was used to determine the
risk. After discussion between review authors, a con-
sensus of 15 % cut-off for attrition bias was agreed
upon [39]. The seventh question addresses selective
reporting by comparing the outcomes pre-specified in
the methods with those presented in the results.
Within the domain “Other bias”, two questions cover
the use of intention-to-treat analysis and whether the
treatment and control groups were similar at baseline.
Although not pre-specified in Cochrane’s risk of bias
[36], these two sources of bias are assessed in a var-
iety of other RCT quality scales [38].
Similar to the protocol of van Middelkoop et al. [35],
each study will be categorised as “low risk of bias” if it
meets at least five of the criteria items in the list. Studies
will then be categorised as “low risk of bias”, “high risk
of bias” or “unclear”. With the exception of non-English
publications, the quality assessment of each study will be
undertaken independently by two authors. If the data ex-
tracted is from a study in a language not spoken by ei-
ther or both authors, the risk of bias assessment will be
done only by the author or a colleague that speaks the
language. The risk of bias score will be used to assess
study-level predictors of response.
In addition, the quality of the IPD data will be assessed.
The quality indicators include number of trials eligible per
treatment, number of trials with the IPD data obtained
and percentage of the data obtained per trial.
In order to determine how representative the IPD ana-
lysis is, a comparison will be made of the patient character-
istics between all eligible trials and those where IPD was
obtained. Characteristics of studies that are not included,
due to missing raw data, unwillingness to collaborate or in-
ability to reach study authors, will be presented and com-
pared to those of the included studies. Furthermore,
sensitivity analyses will be conducted to compare the sum-
mary effects of the included studies with the summary ef-
fects extracted from the published reports of the studies
that were not included. Finally, assessments of funnel plot
asymmetry will be conducted to assess for publication bias.
Data analysis
Once data have been received, the databases will be
cleaned and merged. Means and standard deviations will
be used to describe normally distributed continuous
data, medians and interquartile ranges will be used to
describe continuous data that are not normally distrib-
uted, and frequencies and percentages will be used for
categorical data. Data will be described using 95 % confi-
dence intervals. P values <0.05 will be considered signifi-
cant. Any missing data will be presumed to be missing
at random; therefore, a multiple imputation method will
be used within each trial before pooling the data. I2 will
be calculated as a measure of the heterogeneity of the
included trials. Data analysis will be conducted using the
statistical program Stata SE 14 (StataCorp, College
Station, Texas).
The primary outcome will be pain at 4 weeks of treat-
ment duration or closest to 4 weeks. Secondary outcomes
will include pain at other durations of follow-up, area under
the curve (AUC) for pain scores at the different time points,
function and global assessment measures.
Table 1 Modified risk of bias assessment
Modified from Cochrane’s risk of bias tool [36]
aSee Additional file 2 for criteria for a judgement of “yes”
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A conventional meta-analysis will be undertaken using
study-level variables such as mean pain score, mean age,
mean BMI and sample size. This analysis will help to de-
termine the treatment effect and its variation between
studies. A network meta-analysis will be conducted to
determine the relative efficacy between topical NSAIDs
and capsaicin. Finally, an IPD meta-analysis will be con-
ducted, using both study-level and IPD-level variables,
to determine the treatment effect and its potential pre-
dictors. Both a one-stage (primary) and two-stage (sec-
ondary) approach will be used, and a sensitivity analysis
will be undertaken to compare the findings.
Conventional meta-analysis
Overall analysis An aggregate data meta-analysis, using
a random-effects model, will be performed to estimate
the treatment effect of topical NSAIDs and topical cap-
saicin over placebo. This will be used for the sensitivity
analyses comparing the treatment effect in the studies
included in the IPD analysis with all eligible studies. The
relative efficacy between the two drugs will be examined
directly by comparing topical NSAIDs and topical capsa-
icin within any available head-to-head comparison trials
and indirectly by conducting a network meta-analysis
using a common comparator.
Subgroup analysis When sufficient data are available,
subgroup analysis will be performed for the primary out-
come—pain at 4 weeks according to pain elsewhere
(yes/no), type of pain (dull/neuropathic), pain severity
(low/high intensity), disease severity (marked/modest
disease radiographically), level of inflammation (low/
high) and duration of pain.
Network meta-analysis A number of trials have been
undertaken for topical NSAIDs and topical capsaicin in
OA. However, there are no head-to-head comparisons
between these two commonly used topical analgesics.
Due to the different mechanisms of actions, we assume
that topical capsaicin may be better than NSAIDs in
neuropathic-like pain, such as post-herpetic neuralgia,
diabetic neuropathy and end-stage stage OA with more
neuropathic damage. This begs a comparison between
these two agents in different pain models. A network
meta-analysis has therefore been proposed [40].
We will use topical placebo as a common comparator
(or “node”) to network topical NSAIDs and topical cap-
saicin in each condition to calculate the relative differ-
ence between the two active treatments. To maximise
the information, we will also include trials comparing
topical NSAIDs or capsaicin (if any exist) with oral
NSAIDs or other analgesics. In this scenario, oral
NSAIDs or other analgesics will be the “node” to link
topical NSAIDs and topical capsaicin. If needed, more
than one “node” will be used to link the two treatments,
and a more complicated network may be developed.
Once the network is developed, the relative efficacy
between topical NSAIDs and topical capsaicin will be
calculated. Statistical pooling will be undertaken tak-
ing into consideration the variations between studies
and comparisons. In order to increase the precision
of the estimate, the Bayesian statistical approach will
be applied [41].
IPD meta-analysis
Two-stage modelling A regression model, adjusted for
baseline pain severity using an analysis of covariance
(ANCOVA) method, will be developed for each trial and
the interaction/predictor terms from these models will
be pooled between trials. Depending on the definition of
the treatment effect (dependent variable), the model will
be built with or without interaction terms in order to
identify the predictors. For the specific treatment effect
(i.e. the difference between treatment and placebo), an
interaction term between treatment and potential pre-
dictor will be used to define the predictors of treatment
response. The partial regression coefficient of this inter-
action will be selected and pooled with the same inter-
action terms obtained from the other trials. For the
overall treatment response (i.e. improvement from base-
line), the prediction model is developed within each
arm; therefore, there is no need to use an interaction
term to identify a predictor. In this case, the partial
regression coefficient of the predictor will be used and
pooled between trials. The interaction/predictor terms
will be pooled using a random-effects meta-analytic
technique, based on the inverse-variance method.
One-stage modelling Treatment responders will be de-
termined using a one-step random-effects IPD meta-
analysis approach, i.e. taking into account both study-
level and individual patient-level covariates in the regres-
sion model. All variables listed under the “Data extrac-
tion” section will be considered potential predictors.
Individual patient-level covariates will be centred to the
mean of the covariate in each trial. In order to quantify
the presence of ecological bias, the study-specific mean
of the covariate will also be used. The overall treatment
effect (i.e. change from baseline in participants in the
treatment group) and specific treatment effect (i.e. dif-
ference between treatment and placebo) will be calcu-
lated [42]. Two multilevel regression models will be
developed to consider patient-level and study-level (i.e.
cluster) effects, one to examine predictors of the specific
treatment effect and the other to examine the predictors
of the overall treatment effect. Models will be built with
one potential predictor and interaction term (random-
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effects), and will be adjusted for trial (random intercept),
baseline pain score and other covariates (fixed effects).
The first model will include participants from both
intervention groups where the specific treatment effect
(i.e. change from baseline in both groups) will be the
dependent variable and treatment (active or placebo)
and patient characteristics will be independent variables.
The interaction between the treatment and predictor
will be used to identify the effect modifiers.
The second model will only include participants in the
treatment group, where the overall treatment effect will
be the dependent variable (i.e. change from baseline in
treatment group) and patient characteristics will be inde-
pendent variables. This model is based on the assump-
tion that any treatment effect includes both specific and
non-specific contextual effects (i.e. placebo effect) [42],
and in clinical practice, we only give treatment not pla-
cebo. The aim of this model is to identify the treatment
responders and factors related to the response.
Exploratory analyses Identifying treatment responders
in a clinical setting, where placebo is not used, requires
careful examination of the differences between baseline
pain scores and endpoint pain scores. A receiver operat-
ing characteristic (ROC) curve will be used to find the
cut-off point that gives the best separation between
baseline and endpoint scores, i.e. the most sensitive and
specific threshold. Alternatively, a threshold of 20 % pain
reduction from baseline may be used [43]. Once a
threshold for response has been established, a binomial
model will be developed as appropriate. The model will
be built as described in “One-stage modelling” but will
use logistic regression and responder/non-responder as
the dependent variable.
Potential predictors All baseline variables described in
the “Data extraction” section will be considered potential
predictors of treatment response. As a minimum, we will
utilise age, gender, BMI, baseline pain, pain elsewhere,
evidence of inflammation (clinical or imaging) and
radiographic findings as patient-level variables. For
study-level variables, we will include joint treated, sam-
ple size, setting (community/hospital) and allocation
concealment as a minimum.
Discussion
An IPD meta-analysis forms a part of precision medi-
cine. It helps identify potential predictors of treatment
response at a patient level, which is not possible with
conventional meta-analyses. As the IPD meta-analysis
combines multiple trials with the same treatment and
control, it increases the power of the study, thereby per-
mitting subgroup analysis. Individual trials, on the other
hand, are often not powered for these types of analyses.
Conducting IPD analyses has therefore become very
popular, and a proposal by the International Committee
of Medical Journal Editors (ICMJE) aims to incorporate
it in the publication criteria for trials. As such, trials may
only be published if the de-identified IPD are made
available within 6 months of publication [44].
There are, however, some caveats associated with ana-
lysis. Firstly, not all predictors of response have been
collected in the existing trials. This is the case, even for
trials with the same treatment and control groups, as
every trial has its own hypothesis and primary outcome
measures. It is very difficult to acquire data for a specific
question from all studies, especially data related to sub-
group indicators. This limits the IPD analysis to predic-
tors that are available in the eligible studies. Secondly, it
may not be possible to contact original trial authors, au-
thors may not be willing to collaborate, or they may not
have access to the raw data required [45, 46]. These dif-
ficulties, if not overcome, may introduce bias to the
meta-analysis if the studies not included are systematic-
ally different from those included [45–47]. Several
methods for overcoming these difficulties will be used,
including providing de-identified data [46], facilitating
the process of data collection for original authors by
accepting the data in any format or manner [45, 47] and
pooling resources in the form of collaborative groups
[46]. We hope that in the near future, an organisation or
databank, like the Cochrane Library, will be developed
for IPD as this will better the field of evidence-based
medicine.
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